Literature DB >> 32027502

EGF-Containing Membrane-Bound Mucins: A Hidden ErbB2 Targeting Pathway?

Maxime Liberelle1,2, Nicolas Jonckheere1,3, Patricia Melnyk1,2, Isabelle Van Seuningen1,3, Nicolas Lebègue1,2.   

Abstract

Membrane-bound mucins belong to a heterogeneous family of large O-glycoproteins involved in numerous cancers and inflammatory diseases of the epithelium. Some of them are also involved in protein-protein interactions, with receptor tyrosine kinase ErbB2, and fundamental and clinical data showed that these complexes have a detrimental impact on cancer outcome, thus raising interest in therapeutic targeting. This paper aims to demonstrate that MUC3, MUC4, MUC12, MUC13, and MUC17 have a common evolutionary origin and share a common structural organization with EGF-like and SEA domains. Theoretical structure-function relationship analysis of the conserved domains indicated that the studied membrane-bound mucins share common biological properties along with potential specific functions. Finally, the potential druggability of these complexes is discussed, revealing ErbB2-related pathways of cell signaling to be targeted.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32027502     DOI: 10.1021/acs.jmedchem.9b02001

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  MicroRNA-133a-3p suppresses malignant behavior of non-small cell lung cancer cells by negatively regulating ERBB2.

Authors:  Yanhui Xu; Lei Zhang; Lilong Xia; Xinhai Zhu
Journal:  Oncol Lett       Date:  2021-04-08       Impact factor: 2.967

2.  Single Circulating-Tumor-Cell-Targeted Sequencing to Identify Somatic Variants in Liquid Biopsies in Non-Small-Cell Lung Cancer Patients.

Authors:  Mouadh Barbirou; Amanda Miller; Yariswamy Manjunath; Arturo B Ramirez; Nolan G Ericson; Kevin F Staveley-O'Carroll; Jonathan B Mitchem; Wesley C Warren; Aadel A Chaudhuri; Yi Huang; Guangfu Li; Peter J Tonellato; Jussuf T Kaifi
Journal:  Curr Issues Mol Biol       Date:  2022-02-02       Impact factor: 2.976

3.  MUC3A induces PD-L1 and reduces tyrosine kinase inhibitors effects in EGFR-mutant non-small cell lung cancer.

Authors:  Yuan Luo; Shijing Ma; Yingming Sun; Shan Peng; Zihang Zeng; Linzhi Han; Shuying Li; Wenjie Sun; Jieyu Xu; Xiaoli Tian; Feng Wang; Qiuji Wu; Yu Xiao; Junhong Zhang; Yan Gong; Conghua Xie
Journal:  Int J Biol Sci       Date:  2021-04-12       Impact factor: 6.580

4.  Antagonistic Roles of the Tumor Suppressor miR-210-3p and Oncomucin MUC4 Forming a Negative Feedback Loop in Pancreatic Adenocarcinoma.

Authors:  Nihad Boukrout; Mouloud Souidi; Fatima Lahdaoui; Belinda Duchêne; Bernadette Neve; Lucie Coppin; Emmanuelle Leteurtre; Jérôme Torrisani; Isabelle Van Seuningen; Nicolas Jonckheere
Journal:  Cancers (Basel)       Date:  2021-12-09       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.